Insitro

Insitro combines large-scale biological data generation with machine learning to transform drug discovery. Founded by Daphne Koller, one of the world's foremost AI researchers, the company creates massive datasets from iPSC-derived cell models and patient cohorts, then applies ML to discover novel targets, biomarkers, and drug candidates. Insitro has partnered with Eli Lilly to apply its platform in metabolic disease.

Platform that generates large-scale biological datasets from iPSC-derived cell models, patient-derived samples, and clinical cohorts, then applies ML to map genotype-to-phenotype relationships, discover disease-relevant targets, identify patient stratification biomarkers, and design drug candidates.